D-916
N-Desmethylclomipramine hydrochloride solution
1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H21ClN2 · HCl
化学文摘社编号:
分子量:
337.29
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
InChI
1S/C18H21ClN2.ClH/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21;/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3;1H
InChI key
KMDDAZOLOSKTKZ-UHFFFAOYSA-N
SMILES string
ClC1=CC2=C(C=C1)CCC3=C(C=CC=C3)N2CCCNC.[H]Cl
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol (as free base)
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
General description
N-Desmethylclomipramine is a primary plasma metabolite of the tricyclic antidepressant clomipramine. Clomipramine is a tricyclic antidepressant used to treat many conditions from major depression and panic disorder to narcolepsy and obsessive compulsion disorder (OCD). This Certified Snap-N-Spike® Solution is applicable for use in urine drug testing, clinical toxicology, or forensic analysis by LC-MS/MS or GC/MS.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Clinical pharmacology and therapeutics, 66(2), 152-165 (1999-08-25)
To examine the problems of establishing dose-effect and concentration-effect relationships of antidepressant therapy with clomipramine. This randomized double-blind study compared five fixed doses of clomipramine hydrochloride: 25, 50, 75, 125, and 200 mg/day in hospitalized or day patients at nine
O Dale et al.
Veterinary and human toxicology, 36(4), 309-310 (1994-08-01)
A 27-y-old male was admitted deeply comatosed 5-6 h after taking approximately 15 g clomipramine. The prominent feature of the case was a biphasic course of clomipramine and desmethylclomipramine serum concentrations, possibly caused by delayed drug absorption. Clinically, 2 serious
Mario Rossi et al.
Journal of cell science, 122(Pt 18), 3330-3339 (2009-08-27)
Alterations in the autophagic pathway are associated with the onset and progression of various diseases. However, despite the therapeutic potential for pharmacological modulators of autophagic flux, few such compounds have been characterised. Here we show that clomipramine, an FDA-approved drug
K Shimoda et al.
Journal of clinical psychopharmacology, 19(5), 393-400 (1999-10-03)
The aim of this study was to compare the disposition of the tricyclic antidepressant clomipramine (C) in Japanese and Swedish patients receiving continuous treatment. Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving
F Coudoré et al.
Journal of analytical toxicology, 20(2), 101-105 (1996-03-01)
A rapid and efficient high-performance liquid chromatographic method using a reversed-phase eluent of methanol-water with butylamine on a silica column was developed for the separation and quantitation of clomipramine (CMI), its demethylated metabolites (desmethyl-clomipramine and didesmethyl-clomipramine [DDCMI]), and its hydroxylated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持